Latest news with #IndiraIVF
&w=3840&q=100)
Business Standard
7 days ago
- Business
- Business Standard
EQT-backed Indira IVF refiles DRHP through Sebi's confidential route
Udaipur-headquartered fertility firm Indira IVF, owned by global investment company EQT, has refiled its draft red herring prospectus (DRHP) through market regulator Securities and Exchange Board of India (Sebi)'s confidential pre-filing route. 'The filing of the pre-filed DRHP shall not necessarily mean that the company will undertake the initial public offering (IPO),' the company said in a public announcement. According to people in the know, the company will be looking to repeat its Rs 3,500 crore IPO. The company had initially submitted a draft prospectus in February but withdrew it later, as the IPO plans coincided with the release of a Bollywood biopic based on the company's founder, drawing concerns from Sebi. This development comes amid growing investor interest in the Indian assisted reproductive technology (ART) sector, buoyed by increasing awareness, expanding market size, and favourable demographics. Founded by Ajay Murdia in 1988, Indira IVF is the market leader in assisted reproductive technology services in India and completes roughly 40,000 IVF cycles annually. It also ranks among the top five players globally. Indira IVF's decision to pursue the confidential filing route comes at a time when the method is increasingly popular among startups. The confidential filing route, introduced in 2022, enables companies to withhold sensitive information from the public domain until they are ready to proceed with their IPO. This approach helps issuers avoid unwarranted public scrutiny and opportunistic litigation. In April 2024, food delivery giant Swiggy also opted for the pre-filing route for its IPO. To date, only Swiggy and Vishal Mega Mart have successfully gone public after making confidential filings. Meesho, for instance, filed for a Rs 4,250 crore IPO via the confidential route earlier this month. Tata Play was the first company to utilise this route, though it eventually scrapped its IPO plans. According to sources, Gaudium IVF and Women Health, another prominent player in the fertility care space, is also preparing to refile its DRHP in the immediate future. India completes around 300,000 IVF cycles annually, with the number of cycles expected to grow around 15 per cent at a compound annual growth rate (CAGR) over the next decade. This trend is supported by rising awareness about infertility treatments, a growing middle class, declining fertility rates, and increasing marriage age.
Economic Times
16-07-2025
- Business
- Economic Times
Indira IVF IPO: EQT-backed fertility clinic chain refiles draft papers with Sebi via confidential route
Fertility chain Indira IVF has refiled its Draft Red Herring Prospectus (DRHP) through the confidential filing route, reviving its public listing plans, according to sources. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Fertility chain Indira IVF has refiled its Draft Red Herring Prospectus (DRHP) through the confidential filing route, reviving its public listing plans, according to move comes amidst growing investor interest in the Indian assisted reproductive technology (ART) sector, buoyed by increasing awareness, expanding market size, and favorable people familiar with the matter, Bloomberg on Tuesday had reported that Indira IVF Hospital will soon submit preliminary documents for a listing that may fetch Rs 3,500 crore ($408 million).The company is backed by private equity firm EQT AB. The deal won't involve the issue of new stock as existing shareholders will be selling their holdings, the report said, quoting the will probably offload 29 billion rupees of shares in the offering, and three members of the founding family — Ajay Murdia, Kshitiz Murdia and Nitiz Murdia — will each sell shares worth 2 billion rupees, the people company had initially submitted a draft prospectus in February but withdrew it in March. The withdrawal came as the IPO plans coincided with the release of a Bollywood biopic based on the company's founder, which drew concerns from the Securities and Exchange Board of developments signal renewed IPO momentum in India's fertility and women's health segment, with investors closely watching how these companies position themselves in a competitive and rapidly evolving healthcare Mahindra Capital Co., IIFL Capital Services Ltd. , JPMorgan Chase & Co. and UBS Group AG are advising on the as per sources, Gaudium IVF and Women Health, another prominent player in the fertility care space, is also preparing to refile its DRHP in the immediate future, as part of its continued efforts to tap into capital markets and fuel its next phase of growth.
Time of India
16-07-2025
- Business
- Time of India
Indira IVF IPO: EQT-backed fertility clinic chain refiles draft papers with Sebi via confidential route
Fertility chain Indira IVF has refiled its Draft Red Herring Prospectus (DRHP) through the confidential filing route, reviving its public listing plans, according to sources. The move comes amidst growing investor interest in the Indian assisted reproductive technology (ART) sector, buoyed by increasing awareness, expanding market size, and favorable demographics. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like SRM Online MBA | India's top ranked institute SRM Online Learn More Undo Citing people familiar with the matter, Bloomberg on Tuesday had reported that Indira IVF Hospital will soon submit preliminary documents for a listing that may fetch Rs 3,500 crore ($408 million). The company is backed by private equity firm EQT AB. The deal won't involve the issue of new stock as existing shareholders will be selling their holdings, the report said, quoting the sources. EQT will probably offload 29 billion rupees of shares in the offering, and three members of the founding family — Ajay Murdia, Kshitiz Murdia and Nitiz Murdia — will each sell shares worth 2 billion rupees, the people said. Live Events The company had initially submitted a draft prospectus in February but withdrew it in March. The withdrawal came as the IPO plans coincided with the release of a Bollywood biopic based on the company's founder, which drew concerns from the Securities and Exchange Board of India. Both developments signal renewed IPO momentum in India's fertility and women's health segment, with investors closely watching how these companies position themselves in a competitive and rapidly evolving healthcare vertical. Kotak Mahindra Capital Co., IIFL Capital Services Ltd. , JPMorgan Chase & Co. and UBS Group AG are advising on the IPO. Meanwhile, as per sources, Gaudium IVF and Women Health, another prominent player in the fertility care space, is also preparing to refile its DRHP in the immediate future, as part of its continued efforts to tap into capital markets and fuel its next phase of growth.
Mint
16-07-2025
- Business
- Mint
Upcoming IPO: Indira IVF Hospital files for public offer via confidential route
Upcoming IPO: Indian fertility services provider Indira IVF Hospital joined several other companies that have filed their draft red papers with the stock market regulator Securities and Exchange Board of India (Sebi) for an initial public offering (IPO) via the confidential route, a newspaper advertisement showed on Wednesday. This public announcement is being made to inform the public that the company has filed the pre-filed DRHP with SEBI in relation to the proposed initial public offering of its equity shares on the mainboard of the Stock Exchanges, Indira IVF said, according to the advertisement. The confidential route allows companies to submit draft IPO papers to Sebi for feedback without making the details public, giving them greater flexibility on timing and disclosure. According to a Bloomberg report on Tuesday, Indira IVF's IPO size could be around ₹ 3500 crore. The deal won't involve the issue of new stock as existing shareholders will be selling their holdings, the Bloomberg report added. The report further added that EQT will likely offload ₹ 2,900 crore of shares via the public offer, and three members of the founding family — Ajay Murdia, Kshitiz Murdia and Nitiz Murdia — will each sell shares worth ₹ 200 crore. Indira IVF withdrew its IPO draft filed in February after concerns arose from SEBI about the timing, as it coincided with the release of a Bollywood biopic on its founder. Founded in 2011, the company runs over 155 fertility centres and collaborates with 315 IVF specialists across India, based on its earlier prospectus submitted in September 2024. Meanwhile, according to media sources Gaudium IVF and Women Health, another prominent player in the fertility care space, is also preparing to refile its DRHP in the immediate future, as part of its continued efforts to tap into capital markets and fuel its next phase of growth. Several companies like INOX Clean Energy, Shadowfax Technologies, Shiprocket, Tata Capital and PhysicsWallah and boAt among others have chosen to file IPO papers via confidential route. Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
&w=3840&q=100)
Business Standard
16-07-2025
- Business
- Business Standard
Indira IVF refiles draft IPO via confidential route; Gaudium to follow
Fertility services provider Indira IVF Hospital Ltd has confidentially filed draft papers with markets regulator Sebi to raise funds through an initial public offering (IPO), according to a public announcement on Wednesday. The development comes amidst growing investor interest in the Indian assisted reproductive technology (ART) sector, buoyed by increasing awareness, expanding market size, and favourable demographics. In a public announcement, Indira IVF stated that it has submitted "the pre-filed draft red herring prospectus with Sebi and the stock exchanges... in relation to the proposed initial public offering of its equity shares on the main board of the stock exchanges." The confidential pre-filing route allows the company to withhold public disclosure of details under the draft red herring prospectus (DRHP). Further, pre-filing DRHP does not guarantee the company will go ahead with the initial public offering (IPO). Meanwhile, market sources said Gaudium IVF and Women Health, another prominent player in the fertility care space, is also preparing to refile its draft papers in the immediate future, as part of its efforts to tap into capital markets and fuel its next phase of growth. Both developments signal renewed IPO momentum in India's fertility and women's health segment. Indira IVF had earlier filed preliminary IPO papers through the confidential route in February. However, it withdrew the documents in March. The withdrawal of documents for a market debut coincided with the release of a Bollywood biopic on the company's founder, Ajay Murdia. Reports had indicated that Sebi had taken notice of the situation and raised concerns about Indira IVF's potential indirect self-promotion at a time when details of the IPO were not yet disclosed to the public. Indira IVF Hospital's spokesperson had stated, "The company had decided to withdraw the pre-filed DRHP pursuant to evaluation of various factors and commercial considerations. Reports that suggest any direction from Sebi in this regard are incorrect". The company has opted for the confidential pre-filing route, which allows it to withhold public disclosure of IPO details under the draft red herring prospectus (DRHP) until later stages. This route is gaining traction among Indian firms aiming for flexibility in their IPO plans. In recent months, several companies, including INOX Clean Energy, logistics service provider Shadowfax Technologies, Gaja Alternative Asset Management, commerce enablement platform Shiprocket, Tata Capital, edtech unicorn PhysicsWallah and Imagine Marketing, the parent company of wearables brand boAt, chose confidential filings. In 2024, food delivery giant Swiggy and retail chain Vishal Mega Mart floated their IPOs following similar filings.
